HeartBeam (NASDAQ: BEAT) Closes $10M Public Offering to Advance Cardiac Technology Commercialization

HeartBeam (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses, with the transaction completed on April 16, 2026. The offering, supported by key stakeholders including ClearCardio(TM), company leadership and institutional investors, will fund commercialization of HeartBeam’s FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of AI capabilities and general corporate purposes

To view the full press release, visit https://ibn.fm/9iNYY

At a glance

Company: HeartBeam, Inc.
Ticker: NASDAQ: BEAT
Announcement: Financing

Key figures

Shares in offering: 12.5 million
Gross proceeds before expenses: $10 million
Offering completion date: April 16, 2026

Products and programs

12-lead synthesized ECG system
Extended-wear patch
Heart attack detection technologies

About HeartBeam, Inc.

HeartBeam, Inc. is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025(1). The Company holds over 20 issued patents related to technology enablement.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Questions around this news

How does HeartBeam plan to use the money raised?
The company says the offering’s $10 million in gross proceeds, before expenses, will support efforts to bring its FDA-cleared 12-lead synthesized ECG system to market. Other intended uses include work on an extended-wear patch and heart attack detection technologies, expanding AI capabilities, and general corporate needs.
How does a 3D ECG system generate a 12-lead reading?
An ECG records electrical activity associated with the heart. In the platform described in the release, a cable-free device gathers signals along three directions that are not in the same plane; software then uses those signals to produce a 12-lead ECG. The company describes this as a design for portable use outside medical facilities.
What is an underwritten public offering?
In an underwritten public offering, a company sells securities to public investors with the involvement of one or more underwriters. Depending on the arrangement, underwriters may buy securities from the issuer and resell them, or help market the offering and place shares with investors. The specific commitments depend on the deal’s terms.

SEC filings

Earlier from HeartBeam, Inc.

Back to News Center